[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603038":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":20,"studyPopulation":13,"armGroups":21,"interventions":30,"overallOfficials":13,"centralContacts":44,"locations":50,"responsibleParty":67,"collaborators":13,"id":69,"slug":13,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":13,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":13,"studyType":81,"phases":82,"briefSummary":85,"conditions":86,"keywords":13,"overallStatus":53,"whyStopped":13,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Second Affiliated Hospital of Nanchang University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Surgical resection rate","The percentage of patients who underwent surgical resection after induction treatment","At the end of the surgery",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE","Research Title: A Clinical Study on Induction Treatment with Spatial Fractionated Radiotherapy (SFRT) Concurrent with Tislelizumab Plus Platinum-based Doublet Chemotherapy for Initially Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) Research Objective: To explore the efficacy and safety of induction treatment with spatial fractionated radiotherapy (SFRT) concurrent with tislelizumab plus platinum-based doublet chemotherapy for initially unresectable stage III non-small cell lung cancer (NSCLC).\n\nDesign Type: Interventional Study Research Subjects: Patients with non-small cell lung cancer diagnosed by pathological histology or cytology, staged as stage III (T3 - 4N1 - 2M0) according to the 8th edition of AJCC, defined as initially unresectable by the multidisciplinary team (MDT), without known EGFR and ALK mutations, aged ≥ 18 years old, with an ECOG PS score of 0 - 1.\n\nSample Size: 30 cases",[22],{"label":23,"type":24,"description":25,"interventionNames":26},"SFRT concurrent with tislelizumab and platinum - based doublet chemotherapy","EXPERIMENTAL","SFRT concurrent with immunochemotherapy is given q3w for 3 cycles. Here are details:\n\nRadiotherapy: Select several 1 - cm - diameter spherical areas in the primary tumor's hypoxic region, 1.5 - 2 cm apart. Each area receives a single 12 - Gy high - dose radiotherapy, precisely targeting the hypoxic part to enhance the effect.\n\nChemotherapy \\& Immunotherapy: 1 - 3 days after radiotherapy, combine 200 mg of tislelizumab with platinum - based doublet chemotherapy. NSCLC chemo - drug combos vary by pathology. For adenocarcinoma, use pemetrexed (500 mg\u002Fm² d1) + carboplatin (AUC 5, d1). For other types, use albumin - bound paclitaxel (100 mg\u002Fm² d1,8) + carboplatin (AUC 5, d1).",[27,28,29],"Other: Spatially Fractionated Radiotherapy (SFRT)","Drug: Tislelizumab, Carboplatin, Pemetrexed","Drug: Tislelizumab, paclitaxel, Carboplatin",[31,35,40],{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":13},"Spatially Fractionated Radiotherapy (SFRT)","Several spherical volumes (with a diameter of 1 cm) are selected within the hypoxic area of the primary tumor. The distance between each spherical volume is 1.5 - 2 cm, and a high-dose radiotherapy of 12 Gy × 1F is delivered.",[23],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":13},"DRUG","Tislelizumab, Carboplatin, Pemetrexed","For adenocarcinoma, pemetrexed (500 mg\u002Fm², day 1) + carboplatin (AUC 5, day 1) is used.",[23],{"type":36,"name":41,"description":42,"armGroupLabels":43,"otherNames":13},"Tislelizumab, paclitaxel, Carboplatin","For NSCLC with pathological types other than adenocarcinoma, nab-paclitaxel (100 mg\u002Fm² on day 1 and day 8) + carboplatin (AUC 5, day 1) is used.",[23],[45],{"name":46,"role":47,"phone":48,"phoneExt":13,"email":49},"jing cai Jing Cai","CONTACT","15270905381","cjdl879@163.com",[51],{"facility":52,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Nanchang City, Jiangxi Province","RECRUITING","Nanchang","Jiangxi","330000","China","CN",{"type":60,"coordinates":61},"Point",[62,63],115.85306,28.68396,{"lat":63,"lon":62},[66],{"name":46,"role":47,"phone":48,"phoneExt":13,"email":49},{"type":68,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100603038",false,"NCT07131319","SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC","Spatially Fractionated Radiotherapy (SFRT) Synchronized With Tislelizumab Plus Platinum-based Dual-agent Chemotherapy for Induction Treatment of Initially Unresectable Stage Ⅲ Non-small Cell Lung Cancer: A Clinical Study","Inclusion Criteria:\n\n* The patient has histologically or cytologically confirmed stage III non-small cell lung cancer (NSCLC) that is deemed unresectable after discussion in the multidisciplinary team (MDT), which is classified as T3-4N1-2M0 according to the 8th edition of the American Joint Committee on Cancer (AJCC).\n\nExclusion Criteria:\n\n* Has participated in another clinical study using research products within the past 3 weeks.","ALL","18 Years","85 Years",{"count":79,"type":80},30,"ESTIMATED","INTERVENTIONAL",[83,84],"PHASE2","PHASE3","The aim of this clinical trial is to understand whether spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment is effective in treating initially unresectable stage Ⅲ non-small cell lung cancer (NSCLC). It will also explore the safety of this treatment modality. The main questions it aims to answer are:\n\nWill spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment increase the surgical resection rate of patients with initially unresectable stage Ⅲ non-small cell lung cancer? What adverse reactions will patients experience when receiving spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment?",[87],"Non-Small Cell Lung Cancer","2026-06-24",{"date":90,"type":91},"2026-06-25","ACTUAL",{"date":93,"type":91},"2025-04-21",{"date":95,"type":80},"2028-12-31",{"name":5,"class":6},1]